Acceleron
Positive CHMP opinion for BMS and Acceleron’s Reblozyl in transfusion-dependent anaemia sub-populations
May 1, 2020Medical Communications, Sales and Marketing Acceleron, Bristol-Myers Squibb, EU, Reblozyl
Bristol Myers Squibb and Acceleron Pharma’s Reblozyl (luspatercept) has secured a positivr opinion from the European Medicines Agency’s Committee for Medicinal …
Celgene and Acceleron’s Reblozyl secures FDA approval for anaemia in beta thalassaemia
November 11, 2019Sales and Marketing Acceleron, Celgene, Reblozyl, beta thalassaemia, pharma
The FDA has moved to authorise Celgene and Acceleron Pharma’s Reblozyl (luspatercept-aamt) in the treatment of anaemia associated with the …
Acceleron terminates drug candidate following facioscapulohumeral muscular dystrophy failure
September 17, 2019Manufacturing and Production, Research and Development Acceleron, pharma, trial failure
Acceleron Pharma has seen its stock fall by almost 4% after it unveiled new Phase 2 data confirming that its …
Celgene and Acceleron’s blood disorder drug smashes endpoints at Phase 3
July 11, 2018Research and Development Acceleron, Celgene, beta-thalassemia, luspatercept, pharma
Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming …
Latest content
Long-acting therapies set to reshape HIV treatment market
August 21, 2026
MHRA approves Romvimza for tenosynovial giant cell tumour
August 20, 2026
